Clinical Trial Update: A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA

View source ↗

Summary

A completed clinical trial examining the prevalence of the modified citrullinated vimentin antibody (anti-MCV) in Irish rheumatoid arthritis patients and assess…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Rheumatoid Arthritis | Status: COMPLETED